To serve a co-clinical study of PD-1 inhibition for sarcoma, we have described the establishment, qualification, and application of preclinical MRI and CT imaging protocols for longitudinal assessment of therapeutic efficacy in a GEMM of soft tissue sarcoma. This evidence concerns the gene PDCD1 and soft tissue sarcoma.